| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/YIC.0B013E32835281EF |
| P698 | PubMed publication ID | 22395527 |
| P50 | author | Leslie Citrome | Q37840795 |
| Donna P Phillips | Q53466402 | ||
| P2093 | author name string | Antony Loebel | |
| Josephine Cucchiaro | |||
| Satoru Tsuchiya | |||
| Robert Silva | |||
| Kaushik Sarma | |||
| P433 | issue | 3 | |
| P921 | main subject | schizophrenia | Q41112 |
| lurasidone | Q416992 | ||
| P304 | page(s) | 165-176 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | International Clinical Psychopharmacology | Q15751307 |
| P1476 | title | Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study | |
| P478 | volume | 27 |
| Q36489406 | A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia |
| Q36475355 | A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia |
| Q55304752 | A prospective year-long follow-up of lurasidone use in clinical practice: factors predicting treatment persistence. |
| Q30353864 | A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. |
| Q36062184 | An update of safety of clinically used atypical antipsychotics |
| Q38070179 | Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults |
| Q34641561 | Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis |
| Q34073723 | Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study |
| Q41495591 | Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study |
| Q47733836 | Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study |
| Q38546992 | How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia |
| Q34515834 | LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY |
| Q91790829 | Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons |
| Q36035382 | Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia |
| Q89128745 | Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study |
| Q37675302 | Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment |
| Q26752997 | Lurasidone |
| Q38069538 | Lurasidone : in the treatment of schizophrenia |
| Q99402127 | Lurasidone and Risk for Metabolic Syndrome: Results from Short and Long-term Clinical Studies in Patients with Schizophrenia |
| Q37231216 | Lurasidone as a potential therapy for bipolar disorder |
| Q26796437 | Lurasidone for the treatment of bipolar depression: an evidence-based review |
| Q35544274 | Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies |
| Q38045797 | Lurasidone in schizophrenia: new information about dosage and place in therapy |
| Q38537910 | Lurasidone in the treatment of schizophrenia: a critical evaluation |
| Q36444832 | Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression |
| Q38795708 | Lurasidone: an antipsychotic with antidepressant effects in bipolar depression? |
| Q38094930 | Newer antipsychotics and upcoming molecules for schizophrenia |
| Q38085441 | Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia |
| Q38336677 | Potential use of lurasidone for the treatment of bipolar psychosis |
| Q92102152 | Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia |
| Q100736090 | Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia: Results of a 2-Year, Open-Label Extension Study |
| Q26738850 | Schizophrenia relapse, patient considerations, and potential role of lurasidone |
| Q94547427 | Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study |
| Q38473914 | Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment |
| Q58760344 | Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis |
| Q26782978 | The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis |
| Q34477219 | The clinical utility of lurasidone in schizophrenia: patient considerations |
| Q33619940 | The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. |
| Q46622979 | The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis |
| Q34486175 | Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia |
| Q38151453 | Weight considerations in psychotropic drug prescribing and switching |
| Q34033259 | Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians |
Search more.